Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Deutsche Bank AG

by · The Cerbat Gem

Deutsche Bank AG boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 9.7% in the 4th quarter, HoldingsChannel reports. The fund owned 763,926 shares of the biopharmaceutical company’s stock after acquiring an additional 67,245 shares during the period. Deutsche Bank AG’s holdings in Regeneron Pharmaceuticals were worth $589,652,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Focus Partners Advisor Solutions LLC grew its holdings in Regeneron Pharmaceuticals by 51.4% during the 4th quarter. Focus Partners Advisor Solutions LLC now owns 4,403 shares of the biopharmaceutical company’s stock worth $3,399,000 after acquiring an additional 1,494 shares in the last quarter. Waddell & Associates LLC grew its holdings in Regeneron Pharmaceuticals by 63.7% during the 4th quarter. Waddell & Associates LLC now owns 1,185 shares of the biopharmaceutical company’s stock worth $915,000 after acquiring an additional 461 shares in the last quarter. Cerity Partners LLC grew its holdings in Regeneron Pharmaceuticals by 66.7% during the 4th quarter. Cerity Partners LLC now owns 34,227 shares of the biopharmaceutical company’s stock worth $26,418,000 after acquiring an additional 13,693 shares in the last quarter. Orion Investment Co grew its holdings in Regeneron Pharmaceuticals by 0.6% during the 4th quarter. Orion Investment Co now owns 30,812 shares of the biopharmaceutical company’s stock worth $23,783,000 after acquiring an additional 175 shares in the last quarter. Finally, Franklin Resources Inc. grew its holdings in Regeneron Pharmaceuticals by 4.4% during the 4th quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock worth $1,975,990,000 after acquiring an additional 106,861 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Buying and Selling

In related news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the sale, the director owned 17,503 shares in the company, valued at $12,343,815.72. This represents a 0.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts have commented on the stock. Wells Fargo & Company lowered their price target on shares of Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating for the company in a report on Monday, May 18th. Sanford C. Bernstein lowered their price target on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a report on Wednesday, April 8th. TD Cowen boosted their price target on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a report on Thursday, April 23rd. Guggenheim boosted their price target on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a “buy” rating in a report on Friday, May 1st. Finally, Canaccord Genuity Group lowered their price target on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $792.65.

Read Our Latest Stock Report on REGN

Regeneron Pharmaceuticals Stock Up 0.8%

Shares of NASDAQ:REGN opened at $616.18 on Wednesday. The company has a market capitalization of $65.14 billion, a PE ratio of 15.01, a P/E/G ratio of 1.34 and a beta of 0.25. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a twelve month low of $503.25 and a twelve month high of $821.11. The firm has a 50 day simple moving average of $701.59 and a 200-day simple moving average of $741.02.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. During the same quarter in the prior year, the firm earned $8.22 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 19.0% on a year-over-year basis. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were given a $0.94 dividend. The ex-dividend date was Wednesday, May 20th. This represents a $3.76 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is 9.16%.

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Featured Articles

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).